NASDAQ · PSTX
Poseida Therapeutics, Inc.
$9.50$0.00 (0.0%)
Poseida Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.76% below the high.
Loading market information…
NASDAQ · ASLN · USD
Stock price, earnings
Quote as of Jul 18, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow ASLAN Pharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:00 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2022 |
|---|
| Oct 28, 2022 |
| -$6.40+20.0% vs estimate |
| $0.00 |
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$9.50$0.00 (0.0%)
Poseida Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.76% below the high.
$44.15$0.00 (0.0%)
Albireo Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.39% below the high.
$23.01+$0.02 (+0.09%)
Harpoon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
$8.54$0.00 (0.0%)
Chimerix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$12.49$0.00 (0.0%)
Avid Bioservices, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.16% below the high.
$19.00+$0.04 (+0.21%)
Intercept Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.08% below the high.
$15.31-$0.14 (-0.91%)
Icosavax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
$17.16+$15.79 (+1,152.55%)
Ikena Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.29% below the high.
